Premium Company Profile - Amylin Pharmaceuticals

Amylin's main focus is to develop and commercialize products for the treatment of diabetes and obesity. The company's marketed brands consist of Byetta, which is used for the treatment of patients with type 2 diabetes, and Symlin, indicated for use in adults with type 2 or type 1 diabetes.

Report Highlights
Amylin derives its revenues from marketing of pharmaceutical products and from collaborative agreements to develop and commercialize its products in other countries with other pharmaceutical companies. The company's major contributor to revenue growth during 2002-2006 was product sales of Byetta and Symlin. Amylin's biggest contributor to sales growth out to 2010 will remain to be from Byetta sales. Revenues from Byetta during the period 2006-2010 are forecasted to grow at a CAGR of 40% from $430 million to $1,652 million. Apart from in-house research and development, the company aims to leverage its development resources through collaborations with other pharmaceutical and biotechnology companies such as Eli Lilly and Alkermes.
[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 8
Locations and Subsidiaries 10
Company Financials 11
Overview 11
Stock Market Performance 11
P&L 12
Balance Sheet 14
Cash Flow 15
Business Segment Performance 16
Products & Services 18
Marketed Products 18
Pipeline Products 19
Historical Product Sales 22
AC Forecast Product Sales 23
Competitors and Strategic Business Relationships 25
Key Competitors 25
Key Suppliers 25
Key Clients 26
Shareholding Structure 27
Strategy 28
Company View 28
Corporate Strategy 30
SWOT Analysis 32
Overview 32
Strengths 33
Weaknesses 35
Opportunities 36
Threats 38
Value Chain Analysis 40
Overview 40
Discovery and Product Development 40
Sales 41
Scorecard 42
Overview 42
Scorecard Analysis 43
Key Employees 44
List of Key Employees 44
Key Employee Biographies 46
Financial and Operational Overview 56
Financial and Operational Overview 56
Key Industry Specific Ratios 58
APPENDIX 59
Ask the analyst 59
Datamonitor consulting 59
Disclaimer 59
[Inhaltsverzeichnis ausblenden]

Table 1: Amylin - Key Facts 6
Table 2: Amylin - Other Locations and Subsidiaries 10
Table 3: Amylin - Year-End Share Price and Market Capitalization, 2002-2006 ($) 11
Table 4: Amylin - Key Events Impacting Share Price Performance 11
Table 5: Amylin - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
Table 6: Amylin - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 14
Table 7: Amylin – Balance Sheet, 2002-2006 ($ Mn) 14
Table 8: Amylin – Cash Flow, 2002-2006 ($ Mn) 15
Table 9: Amylin - Revenue Breakdown, 2002-2006 ($ Mn) 16
Table 10: Amylin - Marketed Products 18
Table 11: Amylin - In-house Pipeline Products 19
Table 12: Amylin - Collaboration Pipeline Products 20
Table 13: Amylin – Historical Product Sales, 2002-2006 ($ Mn) 22
Table 14: Amylin - Forecast Sales, 2006-2010 ($ Mn) 23
Table 15: Amylin - Key Competitors 25
Table 16: Amylin - Key Suppliers 26
Table 17: Amylin - Key Shareholders 27
Table 18: Amylin - SWOT Analysis Summary 32
Table 19: Amylin - Value Chain Analysis 40
Table 20: Amylin - Scorecard 42
Table 21: Amylin - Key Employees 44
Table 22: Amylin - Financial and Operational Overview 56
Table 23: Amylin - Key Industry Specific Ratios 58


Figure 1: Amylin - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
Figure 2: Amylin - Key Strategic Revenues, 2002-2006 ($ Mn) 17
Figure 3: Amylin - Key Strategic Revenues, 2006-2010 ($ Mn) 24
[Tabellenverzeichnis ausblenden]